71A/G HSD17B5 SNP and Effects of Oral Contraceptive Pill in PCOS Women

Federal University of Rio Grande do Sul49 enrolled

Overview

An association of the single nucleotide polymorphism (SNP) in the promoter gene that codify for 17b-HSD5 enzyme (71A\>G) with polycystic ovary syndrome (PCOS) and hyperandrogenemia has been suggested in previous studies. Given the role of 17b-HSD5 in androgenic metabolism producing testosterone from precursors, the investigators hypothesis is that women with PCOS and with the variant allele G have a poor response on hirsutism and on hormonal and metabolic variables after oral contraceptive pill (OCP) treatment for 6 months.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Polycystic Ovary Syndrome

Interventions

oral contraceptive pillDRUG

ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles

Eligibility

Sex: FEMALEMin age: 15 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hirsute women with polycystic ovary syndrome Exclusion Criteria: * Use of any drugs known to interfere with hormone levels for at least 3 months before the study * Women with type 2 diabetes, homa index \> 3.8, liver or renal disease or thyroid dysfunction * Other hyperandrogenic disorders than PCOS

Outcomes

Primary Outcomes

Changes at Ferriman- Gallwey score

Time frame: 6 months

Secondary Outcomes

Changes at testosterone levels

Time frame: 6 months

Changes in lipid profile

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.